Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848817 | 0.86 | DHODH (0.40) | NR4A2DHODH | |
| SCHEMBL14222752 | 0.85 | HDAC4 (0.38) | STIM1ORAI1ABL1NR4A2DHODH | |
| SCHEMBL12848541 | 0.85 | MAPT (0.35) | STIM1ORAI1NR4A2DHODH | |
| SCHEMBL12848534 | 0.84 | MAPT (0.34) | STIM1ORAI1NR4A2DHODH | |
| SCHEMBL12848538 | 0.83 | ABL1 (0.37) | STIM1ORAI1ABL1DHODH | |
| SCHEMBL12848535 | 0.81 | DHODH (0.51) | NR4A2DHODH | |
| SCHEMBL14222990 | 0.81 | STIM1 (0.34) | STIM1ORAI1HCAR3NPY5RINSR | |
| SCHEMBL12848715 | 0.81 | ABCB1 (0.40) | NPY5RABL1 | |
| SCHEMBL12848819 | 0.80 | MAPT (0.35) | ABL1NR4A2DHODH | |
| SCHEMBL12848711 | 0.80 | ROCK2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NOD2, RORC, NLRP3 | STIM1 739/4885ORAI1 1169/4885ADRA1A 2816/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | STIM1 294/4885ORAI1 1397/4885ADRA1A 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.